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Abstract—Predicting the interaction between a compound and a target is crucial for rapid drug repurposing. Deep learning has been
successfully applied in drug-target affinity (DTA) problem. However, previous deep learning-based methods ignore modeling the direct
interactions between drug and protein residues. This would lead to inaccurate learning of target representation which may change due to
the drug binding effects. In addition, previous DTA methods learn protein representation solely based on a small number of protein
sequences in DTA datasets while neglecting the use of proteins outside of the DTA datasets. We propose GEFA (Graph Early Fusion
Affinity), a novel graph-in-graph neural network with attention mechanism to address the changes in target representation because of the
binding effects. Specifically, a drug is modeled as a graph of atoms, which then serves as a node in a larger graph of residues-drug
complex. The resulting model is an expressive deep nested graph neural network. We also use pre-trained protein representation
powered by the recent effort of learning contextualized protein representation. The experiments are conducted under different settings to
evaluate scenarios such as novel drugs or targets. The results demonstrate the effectiveness of the pre-trained protein embedding and
the advantages our GEFA in modeling the nested graph for drug-target interaction.
Index Terms—Drug-target binding affinity, Graph neural network, Early fusion, Representation change.
F
1 INTRODUCTION
P REDICTING drug-target binding affinity (DTA prediction)is crucial in new drug development as well as drug
repurposing [1]. The gold standard to determine the binding
affinity is by experimental assays but this is prohibitively
expensive as a rapid screening tool as there are over 100
million drug-like compounds [2] and over 5000 potential
protein targets [3]. Therefore, it is necessary to have alter-
native computational methods using simulation or machine
learning to predict the binding affinity of novel drug-target
pairs. Machine learning methods are particularly attractive
because they offer cheap and fast alternatives with reasonable
performance thanks to the large DTA databases [3] that we
can leverage on.
With the advance of machine learning, many compu-
tational prediction methods [4]–[7] have been proposed
to tackling DTA. In recent works, the protein is typically
represented as a string of amino acids denoted by letters
[6]–[8]. The drawback of using protein sequence is that it
can not represent the 3D structure of the protein which
is crucial information for determining the binding affinity
between protein and drug in practice[9]. However, obtaining
the high-resolution 3D structure is a challenging task. A more
practical solution is using the 2D residue contact maps to
represent tertiary protein structure. These maps can now be
determined with reasonable accuracy from deep learning
powered algorithms [10], [11].
The contact map can be naturally modeled using recent
advances in deep learning known as graph neural networks
(GNN). Here each residue is represented as a node in the
graph, and a contact between two residues as an edge. Each
• Tri Minh Nguyen, Thin Nguyen, Thao Minh Le, Truyen Tran are with
the Applied Artificial Intelligence Institute, Deakin University, Victoria,
Australia.
E-mail: (minhtri, thin.nguyen, lethao, truyen.tran)@deakin.edu.au
node is first embedded with a feature vector. The GNN
operates by iteratively sending messages between nodes,
effectively refining the node representation by collecting
information from its neighbors and distant nodes. Then the
protein representation can be pooled from its residues.
Previous deep learning-based DTA prediction methods
[6]–[8], [12] often use the late fusion approach. The late fusion
approach extracts drug and target representation separately
then predicts the binding affinity from the combined rep-
resentation at the very end of the process. However, this
practice ignores the fact that the binding occurs at a pocket
rather than the whole protein. The pocket is a small convex
cave in the 3D structure of the protein that encourages stable
binding of a drug to the protein. Once the drug binds, it
changes the protein functions to have pharmaceutical effects,
hence it can also change the protein structure [13], hence its
representation. As the late fusion approach only combines
drug and target representation extracted from the input, the
change in protein representation due to the binding process
is not addressed. In addition, the model assumes non site-
specific binding, making it difficult to assign the credit to the
sites that interact. It can also result in slower learning rate,
and less interpretable prediction.
To address target protein representation change, we
propose an early-fusion-based approach. Initially, we extract
representation feature for a given drug molecule from its
drug graph structure. Then, the drug representation is
integrated into the protein graph structure before the protein
representation learning phrase. This is basically a graph
structure nested inside another graph structure. This graph-
in-graph neural network design allows the model to learn
changes in protein representation caused by the binding
process with the drug molecule.
Previous works [6]–[8], [14] normally use one-hot encod-
ing to vectorize residues. This conventional approach fails to
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2embed the contextual dependencies between residues as well
as not being able to make use of unlabeled protein sequences.
Recent advances in natural language processing allow to
learn contextual embedding from massive unlabeled data
which are the current state-of-the-art on many tasks [15].
Therefore, we take advantage of the power of the protein
embedding features learned by a protein language modeling
on a large collection of protein sequences, including proteins
that are not available in DTA datasets, to represent the
residues in a given target protein. In this work, we refer
target proteins whose the binding affinities available in the
DTA datasets as labeled ones while proteins that do not exist
in the DTA datasets as unlabeled proteins.
In summary, the contribution of our work is two-fold.
First, we combine the protein sequence embedding feature
and protein contact map to build the graph representa-
tion of a target protein. Second, in order to reflect the
target representation change during the binding process,
we propose a so-called Graph Early Fusion for binding
Affinity prediction (GEFA) for more accurate biological
modeling. We demonstrate the effects of the GEFA on
Davis dataset [16] where it has shown superior perfor-
mance against previous studies on different settings. Our
Python implementation and data are publicly available at
https://github.com/ngminhtri0394/GEFA.
2 RELATED WORKS
2.1 Drug Re-purposing as an Alternative Medication for
Novel Disease
Drug re-purposing [17] is the process of identifying well-
established medications for the novel target disease. The
advantages of this drug re-purposing over developing a com-
pletely novel drug are lower risk and fast-track development
[18]. The process of drug re-purposing consists of three key
steps: identifying the candidate molecules given the target
disease, drug effect assessment in the preclinical trial, and
effectiveness assessment in clinical trial [19]. The first step,
hypothesis generation, is critical as it decides the success of
the whole process. Advanced computational approaches are
used for hypothesis generation. Computational approaches
in drug re-purposing can be categorized into six groups
[19]: genetic association [20], [21], pathway pathing [22]–[24],
retrospective clinical analysis [25]–[27], novel data sources,
signature matching [28]–[30], molecular docking [31]–[33].
2.2 Drug-Target Binding Affinity Prediction Problem
Drug-target binding affinity indicates the strength of the
binding force between the target protein and its ligand
(drug or inhibitor) [34]. The drug-target binding affinity
prediction problem is a regression task predicting the value
of the binding force. The binding strength is measured by
the equilibrium dissociation constant (KD). A smaller KD
value indicates a stronger binding affinity between protein
and ligand [34]. There are two main approaches: structural
approach and non-structural approach [1]. Structural meth-
ods utilize the 3D structure of protein and ligands to run the
interaction simulation between protein and ligand. On the
other hand, the non-structural approach relies on ligand and
protein features such as sequence, hydrophobic, similarity or
other alternative structural information.
2.2.1 Structural Approach
The structure-based approach involves molecular docking,
predicting the three-dimensional structure of the target-
ligand complex. In molecular docking, there are a large
number of target-ligand complex conformations. The con-
formations are evaluated by the scoring function. Based on
the scoring function types, the structural approach can be
categories into three groups [1]: classical scoring function
method [35]–[38], machine learning scoring function method
[39], and deep learning scoring function method [40], [41].
2.3 Non-structural Approach
The non-structural approach solves the binding affinity
regression task without the accurate 3D structure of the
target. Instead of using the 3D coordinate of target and drug
atom. The non-structural approach relies on the drug-drug,
target-target similarity, target and drug atom sequence, and
other alternative structural information such as contact map
or secondary structure.
2.3.1 Representation of Protein in Non-structural Approach
The simplest way to represent a protein chain is by a string
of letters. Twenty alphabet characters are used to encode
twenty types of amino acids. The torsion angle of each amino
acid in the protein sequence is represented as a pair of φ and
ψ angle. Amino acids in protein sequence have one of three
main types of secondary structure: α helix, β pleated sheet,
and coil. Therefore, three alphabet characters are used to
encode the secondary structure. The interaction between two
non-adjacency residues is represented as the contact map or
distance map. Two non-adjacency residues are in contact if
their distance is less than 8 A˚. The contact map is the binary
map showing whether two residues in the protein chain are
in contact.
2.3.2 Kernel Based Approach (KronRLS)
KronRLS [4], [5] uses the kernel-based approach to construct
the similarity between drugs or between target proteins. In
KronRLS, a kernel is a function measuring the similarity
between two molecules. The regularized least squares regres-
sion (RLS) framework is used to predict the binding affinity
values.
2.3.3 Similarity Matching Approach (SimBoost)
SimBoost [42] constructs features for each drug, target, and
drug-target pair from the similarity among drugs and targets.
Then similarity-based features are used as input in a gradient
boosting machine to predict the continuous value of binding
affinity of the drug-target couples.
2.3.4 Deep Learning Based Methods
DeepDTA [6] predicts the binding affinity from the 1D
representation of protein and drug. WideDTA [8] is an
extension of DeepDTA. Protein is represented not only
in sequence but also in motif and domain. The drug is
represented in SMILES and Ligand Maximum Common
Substructures. The method’s drawback is using sequence
to represent drugs and targets. However, the structural
information of the drug and the target plays important
3roles in the drug-target interaction. Instead of using 1D
representation for drug, GraphDTA [7] uses graph to express
the interaction between atoms of the molecules. This allows
modeling the interaction between any two atoms within the
drug molecules. However, the protein is still represented
as sequence which limits the model performance. PADME
[43] uses graph structure to represent the compound and
Protein Sequence Information (PSC descriptors) to represent
the target. The PSC descriptors contains richer information
than the sequence. However, the model performance may
be limited without the structural information. DrugVQA
[12] uses distance map to represent the protein. Sequential
self-attention is used to learn which parts of the protein
interact with the ligand. Multi-head self-attention is used to
learn which atoms in drugs have high contribution to the
drug-target interaction. However, DrugVQA is a supervised
learning method without any pretraining on targets or
drugs. Therefore, it may not cope well with a novel drug or
protein. Graph-CNN [44] pretrains the protein pocket graph
autoencoder by minimizing representation difference. The
binding interaction model has protein pocket graph and 2D
molecular graph as the inputs. The unsupervised learning
helps the model to overcome the limited pocket graph
training data. However, Graph-CNN requires the protein
pockets as target representation which may limit its general
usage. DGraphDTA [14] uses contact map to build protein
graph structure with PSSM, one-hot encoding, and residue
properties as node features. This allows the model to obtain
an accurate protein representation. However, DGraphDTA
ignores the representation change of the target caused by
conformation change. As a result, the target representation
learned by the model may be inaccurate.
3 PROPOSED METHODS
The task of drug-target binding affinity (DTA) problem is
to predict the binding affinity A between a target protein
P and drug compound D. Mathematically, the problem is
formulated as a regression task:
A = Fθ(P,D), (1)
where θ is model parameters of predicting function F .
In this section, we present details of our approach to solve
DTA. In Sec. 3.1 explains the feature representation of target
protein P, followed by the feature representation of drug
compound D in Sec. 3.2. The main contribution of ours is
presented in Sec. 3.3 where we aim at reflecting the changes
in the target protein representation due to the conformation
change.
3.1 Graph Representation of Protein
Previous methods applying deep learning to DTA [6]–[8] use
target protein sequence whose residues are embedded into
vector space, often with one-hot encoding. Subsequently, an
encoder of multiple 1D convolution layers are used to obtain
a final presentation of the protein sequence. This approach
only makes use of the primary structure information of the
target protein sequence. However, the tertiary information is
important for the drug-target interaction [9]. Even though the
3D representation can precisely describe the tertiary structure,
obtaining 3D geometrical structure information of the protein
is time-consuming and challenging. This is even impossible
for some protein types using NMR or X-ray crystallography
[45]. To balance the complexity against efficiency, we utilize
the 2D contact map information as the representation of the
tertiary structure to represent the protein graph structure.
Given that we have the 2D tertiary structure information,
each target protein is considered as a graph structure where
nodes are residues in the protein sequence. Previous studies
[6], [7] use one-hot encoding to vectorize each residue
in a protein sequence. While using one-hot encoding is
convenient, it does not tell the similarity between elements
but consider them equidistant from each other. In addition,
this choice of representation limits the learning capability as
it fails to leverage the contextual dependencies between
residues, which can be estimated through unsupervised
learning. In effect, the learning signals only come from the
limited number of target proteins in a particular dataset.
In fact, there are only 7605 target proteins [3] being used
for the task of drug-target binding affinity (DTA) prediction
while the majority of proteins are not being used. It has
been estimated that there exist over 188 million sequences of
unlabeled target protein sequences[46].
Leveraging this rich set of unlabeled proteins, we utilize
state of the art language modeling methods to learn contex-
tual residue embedding representation. We use embedded
representation learnt from a large collection of unlabeled
protein sequences provided by TAPE [47] instead of one-
hot encoding to represent each node in the protein graph.
To be more specific, it relies on the latest advance of self-
supervised learning which is widely studied in natural
language processing. Self-supervised learning is a subset
of unsupervised learning where the supervision is derived
from the data itself [48]. Generally, a part of data is withheld
and the model is trained to predict it. Language modeling is a
common case of self-supervised learning in natural language
processing in which it learns the representation of sequence
using pretext tasks such as predicting missing token or the
next token in sequence [15]. TAPE is a variant of language
model for protein representation in particular. Subsequently,
given a protein sequence of L residues, the node features of
the protein graph is a set Vp =
{
vi | vi ∈ Rh
}L
i=1
, where h
is the length of the embedding vector vi provided by TAPE.
Each vi is contextual, that is residues occur in the context of
surrounding residues. Therefore, the structural information
is implicitly encoded into the embedding.
We use secondary structure as it decides the backbone
shape of the target protein which also contributes to the
shape of the binding site and overall structure. For each
residue, the secondary structure feature is represented as
the probability of three secondary structure type α helix, β
pleated sheet, and coil.
Solvent accessibility indicates the level of interaction
between residues and drug molecule. Solvent accessibility
is divided into three classes: buried (pACC from 0 to 10),
medium (pACC from 11 to 40), and exposed (pACC from 41
to 100). Residues buried inside the protein core are less likely
to interact with the drug molecule while exposed residues
are more likely to interact with drug molecule. Eventually,
the combination of embedding vector extracted by TAPE,
4secondary structure feature vector, and solvent accessibility
feature vector are used to represent node features of residues
in a target protein graph.
The contact map information provides the contacts
between any two residue nodes in a protein graph. The
sequence information is also retained in the graph structure
in form of edges linking any two nodes of adjacency residues
in the protein sequence. In practice, the contact map and
sequence information are stored as an adjacency matrix Ap.
In the rest of this paper, we denote the protein graph as
Gp = (Vp,Ap), where Vp are residue nodes in the protein
chain.
3.2 Graph Representation of Drugs Compounds
The input drug compound is in the SMILES format. In the
graph representation of molecule, atoms are nodes while the
bonds between atoms are edges. The node feature consists
of five properties: atom symbol, atom degree which is the
total number of bonded atom neighbors, the number of
hydrogens, implicit value of the atom, and whether if the
atom is aromatic. These features are concatenated to form a
multi-dimensional feature. The edges are expressed by an
adjacency list indicating if there are bonds between any two
atoms in the compounds. As the bonds are symmetric, a
drug compound graph is a bidirectional graph. In the later
use of graph representation of a drug compound, we refer it
as Gd = (Vd,Ad), where Vd is atom features and Ad is bonds
between atoms.
3.3 Graph Early Fusion for binding Affinity prediction
(GEFA)
The overall architecture of our proposed method is presented
in Fig.1. Our GEFA takes as input the graph structure of
drug Gd and the graph structure of target Gp and outputs the
prediction of binding affinity. We use Graph Convolutional
Network (GCN) [49] for graph representation. In addition,
we also make use of the well-known residual skip connection
trick to make use of very deep GCNs.
3.3.1 Graph Convolutional Network
GCN is a convolutional network designed specifically for
graph-structured signals. The goal is learn the node-level
representation from a given input graph G = (X ,A) where
X is node feature matrix of N nodes and A ∈ RN×N is the
adjacency matrix that describes the graph structure. Let W l
be the weight matrix at l-th layer, the graph convolution
operation is defined by:
H1 = X , (2)
H l = σ
(
D˜−
1
2 A˜D˜− 12H l−1W l−1
)
, (3)
where A˜ = A+ I is the adjacency matrix with self-loop in
each node. I is the identity matrix and D˜ =∑j A˜ij and σ
is a non-linear function which is a ReLU [50] in our later
experiments.
3.3.2 Deeper GCN with Residual Blocks
In general, a deeper model can generalize better and more
compact than shallow networks[51]. However, stacking the
vanilla GCN often suffers from the problem of gradient
vanishing and numerical instability as a consequence of
matrix multiplication in Eq. 3. To mitigate this problem, we
use the GCN with residual skip-connection proposed in [52].
Similar to the effect of the residual block in the well-known
CNN [53], skip connection in GCN helps to create more
direct gradient flow, hence, allows to go deeper with more
convolution layers. Mathematically, the graph convolution
operation is given by:
H1 =X , (4)
F l(H l−1) =W l−12 σ(AH l−1W l−11 + bl−1), (5)
H l =σ(H l−1 + F l(H l−1)), (6)
where W1,W2 are learnable weight matrices, l is layer-
wise index and σ is a non-linear function which is a ReLU
activation function.
3.3.3 Graph-Graph Integration with Early Fusion
To reflect the changes in representation of a target protein due
to the interaction between drug molecule and protein, we
propose Graph Early Fusion for binding Affinity (GEFA), a
method for migrating the drug molecule graph Gd = (Vd,Ad)
into the protein graph Gp = (Vp,Ap) via a self-attention
mechanism.
We first refine node representations in the drug graph
with a two-layers GCN as in Eq. 3 and residual blocks as in
Eq. 4, 5, 6. Let V ′d = {v′i | v′i ∈ Rh1}Si=1 as node features of
the drug graph after GCN, where S is number of nodes in the
drug graph. Note that v′i contains aggregating information
from its neighbors so we simply use the largest estimated
representation of the refined drug graph as the representation
of the entire graph. This is easily obtained by a max pooling
operation followed by two linear layers for feature projection:
v′max = MaxPool(V ′d), (7)
xd = (W0v
′
max + b0)W1 + b1. (8)
We call the resulted vector xd ∈ Rh1 as the drug molecules
node, where h1 is dimension of xd.
We now explain how we integrate the drug molecules
node xd into the protein graph Gp = (Vp,Ap) which is the
main contribution of our work. The key idea is to use the
drug node xd as an additional node that binds to the target
graph Gp. The edges connecting the drug node and residue
nodes in the protein graph indicate the interaction between
residues and drug molecule as well as the binding site.
Since not every residue contributes equally to the binding
affinity, the edge weights indicate the level of interactions of
each residue with the drug molecule. To learn the level of
contribution, we utilize a self-attention mechanism driven by
the residue features Vp = {vi | vi ∈ Rh2}Li=1, recalling that
L is the length of the protein sequence. The self-attention
mechanism is motivated from the fact that the binding site
of the protein depends on the protein structure. In the other
word, the attention weights tell which residues are more
5likely to participate in the binding process. Mathematically,
the attention weights are given by:
αi = sotfmax(W2tanh(W1vi)), (9)
where
∑L
i=1 αi = 1, vi is the i-th residue feature, and W1
and W2 are the learnable parameters.
Given the drug node xd and its connections to residues
in the target protein graph Gp denoted by {αi}Li=1, we now
construct a cross-domain graph Gpd = {Vpd,Apd} where
Vpd = {Vp, xd} and Apd = {Ap, {αi}Li=1}. Similar to what
we have done with the drug graph earlier, we employ a
two-layers GCN followed by residual blocks to refine the
node representations of the drug-protein graph Gpd.
Before performing the graph feature extraction, the drug
node after fusion v′dp in the refined nodes V ′pd by GCNs
is taken out from the protein graph to ensure that the
graph feature only contains residues nodes. Eventually, we
extract the latent representation of the protein graph with a
global max pooling operator followed by a two-layer linear
network:
v′max = MaxPool(V ′p), (10)
vpd = (W0v
′
max + b0)W1 + b1, (11)
where V ′p = {V ′pd \ v′dp} is the node representations of the
protein graph after removing the drug node.
At the same time, the drug latent vector xd is transformed
into the same dimensional space with v′dp via a linear
transformation. We further obtain the final representation
of drug by combining these two features with a simple
concatenation operator.
vdb = [xd; v
′
dp], (12)
where [ ; ] denotes the concatenation operation of two vectors.
A max-pooling operation is then performed along the chan-
nel dimension to obtain the combined drug representation.
vdc = MaxPool(vdb). (13)
Consequently, the drug vector vdc and the protein latent
vector vpd are concatenated and finally fed into a predictor of
three fully connected layers to predict the binding affinities.
We wish to hypothesize that our early fusion approach
with self-attention has two benefits. First, the early fusion
approach explicitly models interactions between the drug
graph and the target protein graph. Second, the self-attention
allows the learning model to be more interpretable by
showing which residues interact with drug molecules and
how much they contribute to the binding process. We will
back these in our later experiments.
4 EXPERIMENTS
We evaluate our proposed model GEFA on Davis dataset[16]
and compare against a late fusion baseline as well as state-of-
the-art methods including GCNConvNet [7], GINConvNet
[7], DGraphDTA [14]. Among those methods, GCNConvNet
and GINConvNet use protein sequence and drug molecule
graph as the input while DGraphDTA uses a protein graph
built from contact and drug molecule as the input. We present
the qualitative results in Sec. 4.1 and further provide analysis
of our proposed model via extensive ablation studies in
Sec.4.2.
4.1 Quantitative Experiments
4.1.1 Dataset
Davis dataset consists of binding affinity information be-
tween 72 drugs and 442 targets. The binding affinity between
drug and target is measured by KD (kinase dissociation
constant) value [16]. For the Davis dataset, the drug SMILES
sequence of 68 drugs and the target protein sequence of 442
targets from DeepDTA[6] training/test set are used in our
experiments.
There are four experiments settings for four scenarios.
The first experiment setting is the warm setting where both
protein and drug are known to the model. In this case, every
protein and drug appear in training, validation, and test set.
The second experiment is cold-target where proteins are
unknown to the model and drugs are known to the model.
This setting replicates the scenarios of drug repurposing for
a novel target. In this case, each unique protein sequence
only appears in training, validation, or test set. As targets in
the cold-target setting are required to be unique in both train,
validation, and test sets, targets having the same sequence
are filtered out which results in 361 targets. The 361 targets
are split at 0.8/0.2 ratio for training-validation/testing. Then
the training set is split at 0.8/0.2 ratio for training/validation.
The third experiment setting is cold-drug where proteins
are known to the model and drugs are unknown to the model.
In this case, a unique drug only appears in training, valida-
tion, or test set. We conduct the same splitting procedure in
cold-target but applying for drugs.
Finally, the last experiment setting is cold-drug-target
where both drugs and proteins are unknown to the model.
This scenario is the case of novel drugs for the novel target.
In this setting, we conduct the splitting procedure for both
drug and target to ensure training, validation, and testing set
do not share any common drug or target.
4.1.2 Implementation Details
Our methods are implemented using Pytorch. The protein
sequence embedding features are extracted using TAPE-
Protein [54]. The contact map is predicted by RaptorX [55].
The TAPE-Protein uses BERT language modelling [15]. The
output of TAPE-Protein embedding features extraction is a
embedding vector size 768. The graph convolution network
uses the Pytorch geometric library [56]. The model are
trained on 128 mini-batch. The learning rate is 0.0005 in
warm setting. In cold-target, cold-drug, and cold-drug-target
setting, the learning rate is 0.001 as higher learning rate
helps model to have better generalization and less likely to
overfit. The learning rate decay is used. The learning rate is
reduced by 20% every 40 epochs without improvement in
MSE metric in the validation set. Adam optimizer is used.
The model is trained in 1000 epochs.
4.1.3 Evaluation Metrics
The models’ performances are evaluated using Concordance
Index (CI)[57], Mean Squared Error (MSE), Root Mean
Squared Error (RMSE), Pearson[58], and Spearman[59]. CI
measures the quality of the ranking. CI formula is given as:
CI =
1
Z
∑
di>dj
h(bi − bj), (14)
6Fig. 1. Illustration of Graph Early Fusion for binding Affinity prediction (GEFA). The GEFA takes as input the graph representations of a drug molecule
and a protein target. We first use graph convolution network (GCN) for the drug graph feature refinement before applying a max pooling operator to
obtain the estimated representation of the entire drug graph. The drug estimated vector is then used as an additional node to the protein graph,
establishing graph-in-graph representation across domains. Information retrieved from the drug-protein graph along with the drug representation are
finally used as the input for predicting the binding affinities between the given drug molecule and the protein target.
7h(x) =

1, if x > 0
0.5, if x = 0
0, if x < 0
, (15)
where bi is the predicted value for the larger affinity value di,
bj is the predicted value for the smaller affinity value dj , Z
is the normalization constant, and h(x) is the step function.
MSE measures the mean squared error of the predicted
values. MSE formula is given as:
MSE =
1
N
N∑
i=1
(pi − yi)2, (16)
where pi is the predicted value and yi is the ground truth.
RMSE is the square root of MSE.
Pearson measures the linear correlation between the
predicted value p and the ground truth y:
Pearson =
φ(p, y)
φ(p)φ(y)
, (17)
where φ(p, y) is the covariance between the predicted value
and the ground truth.
Spearman measures the rank correlation:
Spearman = 1− 6
∑n
i=1 d
2
i
n(n2 − 1) , (18)
where di is the difference between two ranks in the predicted
values and ground truths.
4.1.4 Results
To compare our early fusion approach with the conventional
late fusion approach, we provide a late fusion baseline model.
Our late fusion baseline model (GLFA - Graph Late Fusion
for binding Affinity) follows the convention model in which
drug and protein representation are learned separately. GLFA
has graph structures of drug and target as the input. Both
graph structures are processed using the two-layers GCN
and residual blocks in parallel to learn the hidden features.
Then, the latent features are obtained by global max pooling
followed by two linear layers. The latent features from both
protein and drug are concatenated before under-going three
fully connected layers. The output of the final fully connected
layers is the binding affinity value of the input drug and
target protein. The late fusion model is a special case of early
fusion where all drug-residues edge weights are set to 0. The
late fusion approach is used as baseline to compare with our
proposed early fusion approach.
We report our late fusion approach, GLFA, and early
fusion approach, GEFA, with previous works in Davis
benchmark on four settings in Table 1. Our proposed method
GEFA consistently outperforms previous works in four
settings. Our proposed methods achieve state-of-the-art
performance across all four settings. Between two late fusion
based methods DGraphDTA [14] and GLFA, our proposed
GLFA method also outperforms DGraphDTA. This follows
our expectations as the embedding feature contains richer
information than one-hot encoding and PSSM. This also
demonstrates the advantage of using the residual block.
DgraphDTA [14], GLFA, and GEFA outperform GINCon-
vNet in all four settings. GINConvNet and GCNConvNet [7]
only use sequence and CNN to learn the target representation.
TABLE 1
The result of quantitative experiments
Architecture RMSE↓ MSE↓ Pearson↑ Spearman↑ CI ↑
Warm start setting
GCNConvNet [7] 0.5331 0.2842 0.8043 0.6609 0.8649
GINConvNet [7] 0.50723 0.2573 0.8245 0.6818 0.8785
DGraphDTA [14] 0.4917 0.2417 0.8378 0.7001 0.8869
GLFA 0.4850 0.2353 0.8412 0.7073 0.8950
GEFA 0.4775 0.2280 0.8467 0.7023 0.8927
Cold-target setting
GCNConvNet [7] 0.7071 0.5000 0.5145 0.4316 0.7293
GINConvNet [7] 0.7144 0.5104 0.5166 0.3904 0.7065
DGraphDTA [14] 0.6855 0.4700 0.5597 0.4941 0.7656
GLFA 0.6732 0.4531 0.5828 0.5228 0.7802
GEFA 0.6584 0.4335 0.6030 0.5506 0.7951
Cold-drug setting
GCNConvNet [7] 0.9723 0.9454 0.3385 0.3764 0.6784
GINConvNet [7] 0.9592 0.9200 0.3779 0.3693 0.6758
DGraphDTA [14] 0.9583 0.9184 0.3610 0.3150 0.5337
GLFA 0.9280 0.8612 0.4023 0.3549 0.6703
GEFA 0.9202 0.8467 0.4515 0.4320 0.7091
Cold-drug-target setting
GCNConvNet [7] 1.0632 1.1304 0.1904 0.1698 0.5782
GINConvNet [7] 1.0651 1.1345 0.1974 0.2763 0.6275
DGraphDTA [14] 1.0749 1.1554 0.0228 0.1795 0.6081
GLFA 1.0698 1.1444 0.3473 0.2901 0.6362
GEFA 0.9949 0.9899 0.3148 0.2932 0.6390
On the other hand, DgraphDTA [14], GLFA, and GEFA use
the graph built from the protein contact map and learn
the target representation using GCN. This demonstrates the
advantage of using the graph representation of the contact
map.
Between our two proposed methods GEFA and GLFA,
the early fusion method GEFA shows advantages over late
fusion method GLFA. This follows our expectation as the
early fusion allows interactions between drug and protein
graph during the graph representation learning phase for
more accurate latent representation.
We can observe a common trend that all models perfor-
mances in the cold-drug setting are lower than performance
in the cold-target setting. The reason is that the number of
unique target sequences in Davis dataset is higher than the
number of unique SMILES sequence. Therefore, models have
more target protein samples to learn the feature space of the
protein.
4.2 Ablation Studies
To understand the contribution of each component to the
overall performance in the early fusion GEFA model, we
remove each component from the GEFA model. We conduct
the ablation experiment using the Davis dataset benchmark
in the warm setting.
First, we evaluate the usage of the embedding feature by
comparing it with the one-hot encoding.
Second, we evaluate the usage of attention mask as the
graph edge. Instead of using attention as drug-residue edge
weight, drug-residue edges are weighted the same as the
residue-residue edges in the target graph.
Third, we evaluate the usage of the 2-layer GCN and
the usage of residual blocks to refine graph structure. As all
residual blocks have shared weight, this reduces the number
of parameters, which may help in the case of over-fitting.
Fourth, we evaluate the residual blocks. We test three
cases: without residual blocks in both protein and drug
8graph, without protein graph residual blocks, and without
drug graph residual blocks.
Finally, we compare the drug representation extracted
from the drug-protein fusion graph and drug representation
extracted from the drug graph. Instead of fusing two types
of drug features followed by pooling, we only use one
type of drug feature to combine with graph-based protein
representation.
TABLE 2
The result of experiment warm setting with different component in Davis
dataset in warm setting. The first row shows proposed GEFA with all
components.)
Architecture RMSE↓ MSE↓ Pearson↑ Spearman↑ CI ↑
GEFA 0.4775 0.2280 0.8467 0.7023 0.8927
One-hot encoding 0.5050 0.2551 0.8274 0.6919 0.8837
W/o attention 0.4887 0.2388 0.8392 0.7014 0.8909
W/o 2-layer GCN 0.4844 0.2346 0.8425 0.6933 0.887
Residual blocks usage
W/o residual blocks 0.4933 0.2434 0.8351 0.686 0.8819
Drug graph res. blocks 0.4944 0.2444 0.8351 0.6874 0.8828
Protein graph res. blocks 0.4873 0.2375 0.8407 0.7045 0.8941
Drug representation choice
Before fusion rep. 0.4806 0.231 0.8448 0.7058 0.8954
After fusion rep. 0.5171 0.2673 0.8174 0.6437 0.8558
As shown in Table. 2, model using the protein embedding
feature has an improvement of 11.85% in MSE and 1.00%
in CI. This emphasizes the advantage of using the protein
embedding feature as the graph node feature.
Using attention mask as the drug-residue edge in protein
graph gains improvement of 4.74% in MSE and 0.20% in
CI. Without the attention mask, we assume that the drug
molecule interacts with all residues in target protein equally.
However, each residue contributes differently to the binding
process. Therefore, it is reasonable to use self-attention to
learn each residue’s contribution level which is used as edge
weight between drug node and residue node.
Using the 2-layers GCN (GEFA in Table. 2) shows
improvement compared to without using 2-layer GCN (w/o
using the 2-layers GCN in Table. 2). Compared to the model
using solely residual blocks as graph refinement (w/o 2-
layer GCN in Table. 2), the model with residual block shows
an advantage over the model with only the 2-layers GCN
(w/o graph residual blocks in Table. 2). Therefore, it can
be suggested that residual blocks have the same or even
better learning ability than the 2-layer GCN. Interestingly,
combining both the 2-layers GCN and residual blocks brings
the best result as shown in the full component model GEFA.
The model using residual blocks in both drug and protein
graph shows an advantage over the model without any
residual blocks. Model having residual blocks for both drug
graph and protein graph gains 6.73% improvement in MSE
over the model without residual blocks. It is interesting
that applying residual blocks only for drug graph slightly
decrease model performance (0.2% decrease in MSE and
0.1% decrease in CI). Adding back residual blocks for protein
graph helps the model to gain 2.43% improvement in MSE.
Stacking residual blocks in protein graph is more crucial in
the early fusion approach as it affects not only protein graph
representation but also the drug node representation.
Finally, we compare the drug representation before and
after the drug-target graph fusion. Model using only drug
representation before fusion shows comparable performance
while the model using drug representation after fusion
suffers 17.24% performance loss in MSE. This indicates that
drug representation before fusion is more useful than after
fusion. The reason is likely due to message passing in graph
neural network. The drug node info is updated from its
neighbor residue nodes. Therefore, this suggests that the
binding process does not bring any signification change to
the ligand latent representation.
4.3 Error Analysis
We analyze how protein sequences are clustered and their ef-
fect on model performance. First, we cluster target sequences
based on BLAST+ similarities using CLANS [60] convex
clustering on a 2D plane. Five major clusters having more
than 10 targets are chosen to analyze the model performance.
The distribution of five clusters in 2D is shown in Fig. 2. The
average absolute errors of five major clusters are displayed
in Fig. 3 and Table. 3. As shown in Fig. 2, cluster 1, 2, 3, and 5
are close to each other in the 2D similarity distribution space.
The average error of cluster 1, 2, 3, and 5 are roughly the
same at 0.2%. On the other hand, cluster 4 has a high distance
to other clusters. There is a significant difference in model
performance in cluster 4 compared to other clusters. There are
two possible explanations. First, good performance is from
the over-representation of specific targets in the training set.
However, this is not the case as in all five clusters the training
sample/testing sample ratio is nearly the same at 0.8/0.2.
Second, the difference in performance is likely due to some
specific characteristics of the cluster such as sequence length,
motif, etc.
Fig. 2. The distribution of five major target sequence clusters.
Fig. 3. The average absolute error of each target by five major clusters.
We analyze the binding site predicted by the GEFA model
in the successful case and the failed case. We choose two
drug-target binding pairs with 3D structure available having
9TABLE 3
The number of training and testing samples, the number of protein, and
average absolute error of five major sequence clusters.)
Cluster No
pairs in
testing
No
pairs in
training
Train/test
ratio
No pro-
teins
Average absolute error
1 2159 10952 0.1971 192 0.2137 (±0.1492)
2 1519 7455 0.2037 132 0.2882 (±0.2059)
3 202 1022 0.1977 18 0.2189 (±0.0849)
4 188 900 0.2089 16 0.0386 (±0.1166)
5 117 563 0.2078 10 0.1923 (±0.1449)
the lowest and highest absolute error. For the successful
case, we analyze the binding between target MST1 and
compound Bosutinib (PubChem CID 5328940) predicted by
our proposed model and compare it with blind docking
simulation [61]. The Bosutinib-MST1 pair has predicted KD
value at 6.72132 with the absolute error at 0.0000738.
Fig. 4. Attention values at predicted binding sites of MST1 target. The
attention value at residue ASP 149.A is 0.2 (20%) , 0.72 (72%) at residue
ASP 167.A, and 0.07 (7%) at residue ASP 206.A
Fig. 5. Residue-ligand interaction between MST1 and Bosutinib predicted
by blind docking.
The attention value from the self-attentive layer of the
MST1 target indicates that the residue ASP 167.A has the
highest probability (0.72) to be the binding site. This agrees
with the blind docking result. In the blind docking simulation
of the Bosutinib-MST1 pair, the conformation with the lowest
binding energy (−7.30kcal/mol) shows the hydrogen bond
between ASP 167.A and the ligand (Fig. 5).
Fig. 6. Predicted binding pocket highlighted in red and the Bosutinib
ligand docking
For the failed case, we analyze the binding between target
EGFR(T790M) and Lapatinib (PubChem CID 208908). The
predicted KD value is 8.7785 while the ground truth value is
6.0655. The attention value obtained from the self-attentive
layer peaks at ASP 896.A with 0.48 (48%) confidence (see Fig.
7). However, in the crystallised structure of EGFR(T790M),
the 896.A residue is buried (see Fig.8) and is less likely to be
the binding site. In addition, the predicted conformation of
blind docking shows no interaction between residue 896.A
and the ligand (see Fig. 9). Therefore, in the early fusion
model, the edges between the drug node and binding site
residue are not correct. As a result, the error of the predicted
KD value of Lapatinib-EGFR(T790M) is one of the highest
in the Davis test set. From two examples of a successful case
and failed case, obtaining the correct binding site to form the
correct drug node - residues edge is one of the important
aspects of the early fusion approach.
Fig. 7. Attention values at predicted binding sites of EGFR(T790M) target.
5 CONCLUSION
We have proposed a novel deep learning method, called
GEFA (Graph Early Fusion for binding Affinity prediction)
for target-drug affinity prediction, a crucial task for rapid
virtual drug screening and drug repurposing. To improve
the power of protein representation, we use self-supervised
to take advantage of a large amount of unlabeled target
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Fig. 8. Solvent-excluded surface areas value of EGFR(T790M) target.
Fig. 9. Residue-ligand interaction between EGFR(T790M) and Lapatinib
predicted by blind docking.
sequences. To address the latent representation change due
to conformation change during the binding process, the early
fusion between drug and target is proposed. Unlike the late
fusion approach extracting representation separately, the
early fusion approach integrates drug representation info
into protein representation learning phase. The self-attention
value of the target sequence is used as edge weight connect-
ing drug node and residue node in the target protein graph.
Self-attention allows the model more interpretable as it shows
which residues contribute to the binding process and the level
of contribution of each residue. The quantitative experiments
show that the early fusion approach has advantages over the
late fusion approach. Using the embedding feature as target
node feature has advantages over using one-hot encoding.
Residual block design allows stacking multiple GCN layers
for better learning representation capability.
This work opens room for future investigations. Even
though the target representation change is addressed by
adding drug node to the target graph during the representa-
tion learning phase, the conformation change, which is the
residue-residue edge connection change, is not addressed.
If we can learn the edge change, we can express the
conformation change caused by the drug-target binding.
In addition, in case the target protein has multiple binding
pocket at different regions, the drug molecule may only
bind at one pocket at one time. However, in our model, the
drug node links to all possible binding sites indicated by
self-attention mask. The binding process modeling will be
more accurate if we can combine drug info into the finding
drug-residues edges process.
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